top
Puberty blocker trial will help reduce harm, says Cass report author
Key takeaways
- Dr Hilary Cass said she was "absolutely convinced that more children will be harmed if we don't do the trial than if we do."
- The Pathways clinical trial will be run by researchers at Kings College, London (KCL).
- The puberty blockers research was recommended by Dr Cass after her 2024 review of gender medicine for children pointed to weak evidence behind their use.
Why this matters: a developing story that could shape the day's news cycle.
Alison Holt,Social affairs editorand James Melley,Senior social affairs producer BBCDame Hilary Cass says puberty blocker trial is "essential" A trial examining the risks or benefits of drugs that can delay puberty for gender-questioning children will help reduce harm, according to the author of a landmark review.
Dr Hilary Cass said she was "absolutely convinced that more children will be harmed if we don't do the trial than if we do."
Her comments follow pressure from campaigners and some politicians to have the research programme scrapped after it was announced children as young as 11 could be recruited onto the trial.
Article preview — originally published by BBC News. Full story at the source.
Read full story on BBC News →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from BBC News alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop